A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia FDA Decision: Karyopharm Therapeutics (KPTI)

The Phase 2 date for A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia by Karyopharm Therapeutics (KPTI) is scheduled for June 1, 2027. This is the target date for the FDA to make a decision on this application.

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia is being developed by Karyopharm Therapeutics for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia receives FDA approval, Karyopharm Therapeutics (KPTI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for KPTI on DilutionWatch at dilutionwatch.com/stock/KPTI.html.

You can view the full BiotechSign company profile for Karyopharm Therapeutics (KPTI) at biotechsign.com/app/company/KPTI, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.